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Finally, immunoproteasome inhibitors will become available for patients with B cell-mediated autoimmunities, which are refractory to currently available treatment options. The new and exciting extension of current treatment options for rheumatoid arthritis, biosimilars, will not be discussed in this review as details on these agents are available in recently published reports. Specifically emerging therapies for RA which are already used in clinical practice or which will become available in the new future are addressed. Biosimilars, the new and exciting extension of current treatment options for RA, will not be discussed in this review as these molecules have been discussed in very recent publications. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. More data from animal studies as well as from phase I/II clinical trials are warranted to determine whether blocking C5 will be an efficacious and alternative treatment principle for RA patients who are or become refractory to the available treatment options. Based on the animal model described here, this monoclonal antibody might be a molecule for intraarticular application. The monoclonal anti-C5 antibody eculizumab has recently been approved for the treatment of the atypical hemolytic-uremic syndrome [34] .
IMMUNE MODULATION BY TREGS

Bispecific Monoclonal Antibodies
Bispecific monoclonal antibodies are frequently used to treat cancer, leukemia, and lymphoma.
A new bispecific monoclonal antibody, anti-CD19/anti-CD3 BITE antibody, has recently been found to be extremely efficacious for the treatment of B-cell leukemia and B-cell lymphoma due to its B-cell deleting action [35, 36] . Taking into consideration that the efficacy of rituximab, a monoclonal antibody, is also mainly due to its B cell-deleting action, an interesting question is 
